Key terms
About ABVC
ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The firm's product pipeline includes ABV-1501, which is a combination therapy for triple negative breast cancer, ABV-1504, which is a botanical reuptake inhibitor that targets norepinephrine, ABV-1505 for treating attention deficit hyperactivity disorder, ABV-1702 to treat myelodysplastic syndromes, ABV-1703 for Pancreatic Cancer, ABV-1601 for treating depression in cancer patients, ABV-1701, which is a vitreous substitute for vitrectomy, ABV-2001, and ABV-2002. The company was founded in 1990 and is headquartered in Fremont, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ABVC news
Yesterday
9:07am ET
ABVC BioPharma executes global licensing agreement for treatment of NSCLC
Mar 21
8:40am ET
AiBtl BioPharma completes $7.6M land deal
Feb 27
8:43am ET
ABVC BioPharma provides update on development of combination therapy
Feb 15
8:39am ET
ABVC enters agreement to license certain healthcare-related expertise to SPI
Feb 12
8:35am ET
ABVC BioPharma receives Australian patent for treatment of MDD
Feb 09
4:22am ET
ABVC BioPharma Expands Footprint with Strategic Land Acquisitions
Feb 09
4:22am ET
ABVC BioPharma Conducts Private Equity and Warrants Sale
Feb 08
9:18am ET
ABVC BioPharma acquires $2.96M worth of land in Asia
No recent press releases are available for ABVC
ABVC Financials
Key terms
Ad Feedback
ABVC Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ABVC Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
